Cyclic-di-GMP disodium c-di-GMP disodium; cyclic diguanylate disodium; 5GP-5GP disodium|cas:2222132-40-1|西域试剂

Cyclic-di-GMP disodium c-di-GMP disodium; cyclic diguanylate disodium; 5GP-5GP disodium,99.23%

产品编号：Bellancom-110382| CAS NO：2222132-40-1| 分子式：C₂₀H₂₂N₁₀Na₂O₁₄P₂| 分子量：734.37

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-110382	￥2500.00	杭州北京（现货）
Bellancom-110382	￥7500.00	杭州北京（现货）
Bellancom-110382	￥12000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Cyclic-di-GMP disodium c-di-GMP disodium; cyclic diguanylate disodium; 5GP-5GP disodium

产品介绍

Cyclic-di-GMP disodium 是一种 STING 激动剂，也是细菌第二信使，协调细菌生长和行为的不同方面，包括运动能力、毒力、生物膜的形成和细胞周期的进展。Cyclic-di-GMP disodium 具有抗癌细胞增殖活性，还可诱导 CD4 受体表达升高和细胞周期停滞。Cyclic-di-GMP disodium 可用于癌症的研究。

生物活性

Cyclic-di-GMP disodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP disodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP disodium can be used in cancer research^[4].

体外研究

Cyclic-di-GMP disodium (0.5-50 µM; 5 days) inhibits proliferation of human colon cancer cells.
Cyclic-di-GMP disodium (0.5-50 µM; 5 days) specifically elevates CD4 expression in Jurkat cells.
Cyclic-di-GMP disodium (0.5-50 µM; 5 days) induces cell cycle arrest at the S-phase in Jurkat cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	H508 cells
Concentration:	0.5-50 µM
Incubation Time:	5 days
Result:	Reduced basal H508 cell proliferation by approx 15%, even inhibited acetylcholine- and EGF-induced cell proliferation.

Cell Viability Assay

Cell Line:	Jurkat cells
Concentration:	50 µM
Incubation Time:	24 h
Result:	Specifically induced of CD4 (no effect on the expression of CD8), with a 6.3-fold upregulation over control and in a dose-dependent manner.

Cell Cycle Analysis

Cell Line:	Jurkat cells
Concentration:	50 µM
Incubation Time:	24 h
Result:	Increased the percentage of cells in S-phase by 79%, with almost complete disappearance of G2/M-phase cells which decreased by 93%.

体内研究
(In Vivo)

Cyclic-di-GMP disodium (100 µg/per; i.v.; two sequential vaccinations 9 days apart) enhances TriVax-induced immune responses to melanoma in mice and further increased the anti-tumor effects of TriVax.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 (B6) mice (8- to 10-week-old).
Dosage:	100 µg/per
Administration:	Intravenous injection; two sequential vaccinations 9 days apart; combine with TriVax.
Result:	Significantly higher numbers of antigen-specific CD8 T cells when combined with TriVax. (TriVax consisted of a mixture of 120 μg Pam-hgp100, 100 µg hgp100 or 100 µg Ova, 50 or 25 μg anti-CD40 antibody, and 25 μg Poly-IC). Enhanced the anti-tumor activity of TriVax.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 (B6) mice (8- to 10-week-old).
Dosage:	100 µg/per
Administration:	Intravenous injection; two sequential vaccinations 9 days apart; combine with TriVax.
Result:	Significantly higher numbers of antigen-specific CD8 T cells when combined with TriVax. (TriVax consisted of a mixture of 120 μg Pam-hgp100, 100 µg hgp100 or 100 µg Ova, 50 or 25 μg anti-CD40 antibody, and 25 μg Poly-IC). Enhanced the anti-tumor activity of TriVax.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 (B6) mice (8- to 10-week-old).
Dosage:	100 µg/per
Administration:	Intravenous injection; two sequential vaccinations 9 days apart; combine with TriVax.
Result:	Significantly higher numbers of antigen-specific CD8 T cells when combined with TriVax. (TriVax consisted of a mixture of 120 μg Pam-hgp100, 100 µg hgp100 or 100 µg Ova, 50 or 25 μg anti-CD40 antibody, and 25 μg Poly-IC). Enhanced the anti-tumor activity of TriVax.

性状

Solid

溶解性数据

In Vitro:

H₂O : 160 mg/mL (217.87 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.3617 mL	6.8086 mL	13.6171 mL
5 mM	0.2723 mL	1.3617 mL	2.7234 mL
10 mM	0.1362 mL	0.6809 mL	1.3617 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months (protect from light, stored under nitrogen)。-80°C 储存时，请在 6 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶